Melasma

La Roche-Posay Unveils Breakthrough Dark Spot Innovation: MelaB3 Serum & UV with Multi-Patented Ingredient Melasyl™ Born from 18 Years of Research

Retrieved on: 
Thursday, April 25, 2024
Dark, Selenium, Skin discoloration, Mineral, Safety, Woman, Skin, UVB, L'Oréal, Nicotinamide, Research, Melasma, Pigment, Science, La Roche-Posay, Complaint, Patient, Element, Quality of life, Smash Mouth, SPF, Cosmetics

NEW YORK, April 25, 2024 /PRNewswire/ -- La Roche-Posay, renowned for its dermatologist-tested skincare solutions, is proud to announce the launch of its latest dark spot innovations – Mela B3 Dark Spot Serum & Mela B3 UV Daily Moisturizer SPF 30.

Key Points: 
  • NEW YORK, April 25, 2024 /PRNewswire/ -- La Roche-Posay, renowned for its dermatologist-tested skincare solutions, is proud to announce the launch of its latest dark spot innovations – Mela B3 Dark Spot Serum & Mela B3 UV Daily Moisturizer SPF 30.
  • Powered by Melasyl™, L'Oreal's new multi-patented ingredient born from 18 years of research, this launch marks a breakthrough in pigmentation science for those dealing with skin discoloration.
  • Born from research on 23,000 people1, Mela B3 Serum is the first dermatological discoloration and dark spot solution powered by Melasyl™ with 10% Niacinamide.
  • Mela B3 serum with Melasyl™ & Niacinamide will improve facial skin discoloration, fade dark spots, and correct uneven skin tone," says board-certified dermatologist Dr. Valerie Callender.

SkinPen® Precision Now Available through DUBIMED in the Gulf States

Retrieved on: 
Friday, April 5, 2024
Growth, International, Patient, Ageing, Medical device, Collagen induction therapy, Dyschromia, Acne, Skin, Access, Crown, Melasma, FDA, Customer service, Neck, Gulf Cooperation Council

DALLAS, April 5, 2024 /PRNewswire/ -- Crown Aesthetics ("Crown"), a division of Crown Laboratories, Inc., is happy to announce that SkinPen® Precision ("SkinPen"), the first microneedling device cleared by the FDA and a global leader in skin remodeling, is now available through DUBIMED Medical Supplies Trading LLC in United Arab Emirates, Qatar, and Oman.

Key Points: 
  • Access to SkinPen will significantly benefit these Gulf States countries' healthcare professionals and their customers.
  • "At DUBIMED, we stand as leaders in the Gulf Cooperation Council for more than 37 years and are committed to bringing cutting-edge aesthetics medical solutions to these markets," said Safi Rajab, CEO of DUBIMED.
  • FDA cleared in 2018 and backed by over 90 validation studies*, SkinPen Precision is a superior skin remodeling device engineered in the USA.
  • Please visit www.skinpeninternational.com
    SkinPen Precision works by creating controlled micro-injuries to stimulate the body's natural wound-healing response and remodel scar tissue.

Prevent Blindness Provides Free Resources as Part of April's Women's Eye Health and Safety Month to Educate Women on Necessary Steps to Help Save Sight

Retrieved on: 
Wednesday, March 27, 2024
Orbis, IOP, Pigment, Glaucoma, Le Bonheur Children's Hospital, Social media, Pressure, Visual impairment, Contact, Paratriathlon, Intraocular pressure, AAO, Policy, Orbis International, Hormone, Diabetes, Risk, Mental health, Delta Gamma, NIH, Eyelid, Prevalence, Eye, Associate, Safety, Cataract, Menopause, University, Pregnancy, Hospital, Melasma, Public health, Lactation, Puberty, American Academy, Lens, Telecanthus, Eye disease, Graves' ophthalmopathy, Bangladesh Technical Education Board, Dry eye syndrome, Pediatrics, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month. According to Orbis International, globally there are 112 million more women than men living with vision loss, including blindness. Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month.
  • Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.
  • Women have a higher prevalence of age-related macular degeneration, cataract, dry eye, glaucoma, refractive error and thyroid eye disease.
  • For more information on women's eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org.

Bionique Launches Even & Renew, the Latest Addition to the Wellbeing Pro Series, Offering Hope for Those Battling Skin Dark Spots and Hyperpigmentation

Retrieved on: 
Sunday, March 24, 2024
Research, Pigment, Antioxidant, Tablet, Prevalence, Name, Beauty, AUST, Skin discoloration, Vitamin C, Skin, TGA, Melasma, Multimedia, Dietary supplement

SYDNEY, March 24, 2024 /PRNewswire-PRWeb/ -- The pursuit of a flawless and even skin tone is a universal desire, with individuals across the globe seeking effective solutions to combat pigmentation issues. Research conducted by ENSOUL Medical Clinic in 2023 has shed light on the prevalence of skin problems related to pigmentation among Asians, stemming from their increased melanin production.

Key Points: 
  • Skin discoloration, often caused by excessive melanin secretion or irregular distribution within the skin, can be influenced by various factors including hormonal imbalances, genetic predisposition, sun exposure, and lifestyle habits.
  • In response to this widespread concern, people continuously explore a myriad of methods to address these issues and achieve their desired complexion.
  • Even & Renew has successfully passed its rigorous review to become an AUST listed product, demonstrating its exceptional quality and significant efficacies.
  • Bionique is dedicated to fulfilling consumers' beauty aspirations by continuing to introduce efficacy-focused oral supplements in the future.

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

Retrieved on: 
Wednesday, March 6, 2024
Lentigo, Pigment, Metabolism, Melasma, Elasticity, UVR, Ageing, Patent, Phio Pharmaceuticals, Skin, Hyperpigmentation, Gene silencing, TYR, Downregulation and upregulation, Iodosobenzene, MMP1, Vaccine

The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.

Key Points: 
  • The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.
  • Ultraviolet radiation (UVR) exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis.
  • “We have a robust patent portfolio for Phio’s INTASYL siRNA technology,” said Robert Bitterman, CEO of Phio Pharmaceuticals.
  • “The addition of this recent patent grant for treatment of photodamaged skin is complementary to our current initiative in treating skin cancer.”

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on: 
Thursday, February 22, 2024
Health, Other Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Therapy, Skin cancer, Neoplasm, Recurrence, Melasma, Scar, Toxicity, Melanocyte, FDA, SKS, Skin, Dermatoscopy, BCC, Entrepreneurship, Hyperpigmentation, Risk, Epidermis, Safety, PLA, Patient, Carcinoma, Laser, Medical imaging

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points: 
  • DermBiont currently anticipates that data will be available in Q3 2024.
  • SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
  • BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
  • Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.

VI Peel® Announces 36% Boost in Anti-Aging Benefits of Botox® from New Clinical Study

Retrieved on: 
Tuesday, February 13, 2024
Pain, Acne, Melasma, ALL, RN, Patient satisfaction, Ageing, JDD, Skin, MBA, Hyperpigmentation, Habit, Patient, Smash Mouth, FAAD, Trial of the century, Cosmetics

"The efficacy of VI Peel and Botox same-day treatment was clinically proven by the improvements to wrinkle severity, uniformity of pigment, and skin tone via photographic matching," Roberts says.

Key Points: 
  • "The efficacy of VI Peel and Botox same-day treatment was clinically proven by the improvements to wrinkle severity, uniformity of pigment, and skin tone via photographic matching," Roberts says.
  • "The clinical significance of this combination will appeal to multi-generational patients where anti-aging and skin health remain at the forefront of their buying habits."
  • This is in direct contrast to the majority of medical or clinical studies that favor Caucasians or lighter Fitzpatrick types.
  • A ToxBooster Treatment combines a VI Peel followed immediately by a Neurotoxin Injection (like Botox®, Xeomin®, Dysport®, Juveau® and Daxxify®).

HH Science™ Receives Brand's 1st U.S. Patent for Balanced Skin™ Clear Skin Vitamins™

Retrieved on: 
Tuesday, January 23, 2024
Hope, Patient, Nutrient, Vitamin, Melasma, Rosacea, Perioral dermatitis, Skin, MBA, Psoriasis, Smash Mouth, Inflammation, Zinc, Acne, Malnutrition, Dermatitis, Atopic dermatitis, Trial of the century, Antioxidant

MEDINA, Ohio, Jan. 23, 2024 /PRNewswire/ -- HH Science™ is proudly announcing the brand's 1st patent for their Balanced Skin™ Clear Skin Vitamins™. The U.S. Patent and Trademark Office has issued patent No. 11,877,998 which will be officially released on January 23, 2024.

Key Points: 
  • The clinical researcher, Dana Pilz, PA-C, was evaluating whether the Clear Skin Vitamins™ contributed to the overall improvement of acne, melasma, inflammation and perioral dermatitis.
  • All the patients except for two were compliant with taking their Clear Skin Vitamins™ daily.
  • In conclusion, the Clear Skin Vitamins™ did contribute to the overall improvement of acne, melasma, rosacea, atopic dermatitis, inflammation, and perioral dermatitis.
  • "We have numerous claims that have been approved that we can now market as being improved from the daily use of our Clear Skin Vitamins™.

Global Microdermabrasion Devices Market Report 2023: A $496 Million Industry in 2022 - Industry Trends, Share, Size, Growth, Opportunity and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Cosmetics, Retail, Health, Consumer, Other Retail, Women, Other Health, Hospital, Melasma, Aluminium, John Foster Dulles, Hyperpigmentation, Skin, COVID-19, Smash Mouth, Vacuum, Collagen, Acne, Ageing, Suction, Prevalence

The "Global Microdermabrasion Devices Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Microdermabrasion Devices Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global microdermabrasion devices market size reached US$ 496.1 Million in 2022.
  • Microdermabrasion devices are mechanical exfoliation equipment used for improving the texture of the skin and reducing the appearance of superficial blemishes.
  • What is the structure of the global microdermabrasion devices market and who are the key players?

DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Olive, FDA, Viking Global Investors, Food, Hyperpigmentation, Therapy, PKC, Skin, DPN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Laser, Melasma, Physician, Recurrence, Venture round, Civilization, Dermatology, Safety, SKS, SK, Series, Patient, AKT, Dermatosis papulosa nigra, Pharmaceutical industry, Dietary supplement

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.

Key Points: 
  • DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.
  • The Series B was led by new institutional investor, Double Point Ventures, and includes continued support from Viking Global Investors, Civilization Ventures, Olive Tree Capital, and others.
  • These products prioritize the patient experience by addressing the root cause of both diseases with excellent efficacy, safety, and tolerability.
  • Phase 2b open label clinical trial in 10 subjects with DPN (Dermatosis Papulosa Nigra) treated with SM-020 gel 1% twice daily for 28 days.